Folger Nolan Fleming Douglas Capital Management Inc. Lowers Position in Johnson & Johnson (NYSE:JNJ)

Folger Nolan Fleming Douglas Capital Management Inc. trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 2.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 103,659 shares of the company’s stock after selling 2,130 shares during the period. Johnson & Johnson makes up approximately 1.6% of Folger Nolan Fleming Douglas Capital Management Inc.’s portfolio, making the stock its 16th biggest holding. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Johnson & Johnson were worth $14,991,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of JNJ. Retirement Wealth Solutions LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at $73,000. Brooklyn Investment Group boosted its position in Johnson & Johnson by 33.2% during the fourth quarter. Brooklyn Investment Group now owns 16,457 shares of the company’s stock valued at $2,380,000 after buying an additional 4,099 shares during the period. Defined Wealth Management LLC grew its stake in shares of Johnson & Johnson by 3.8% during the fourth quarter. Defined Wealth Management LLC now owns 3,063 shares of the company’s stock valued at $443,000 after buying an additional 111 shares during the last quarter. Cranbrook Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 4.8% in the fourth quarter. Cranbrook Wealth Management LLC now owns 4,365 shares of the company’s stock worth $631,000 after buying an additional 200 shares during the period. Finally, Sax Wealth Advisors LLC boosted its holdings in Johnson & Johnson by 17.5% during the 4th quarter. Sax Wealth Advisors LLC now owns 18,938 shares of the company’s stock valued at $2,739,000 after acquiring an additional 2,814 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on JNJ shares. Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Royal Bank of Canada raised their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Citigroup lowered their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $174.29.

Johnson & Johnson Trading Down 0.5 %

NYSE:JNJ opened at $147.03 on Monday. The company has a 50 day simple moving average of $148.51 and a two-hundred day simple moving average of $156.03. The company has a market cap of $353.99 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.37%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 71.78%.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.